合富（中国）医疗科技股份有限公司（以下简称"公司"） 之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司营业收入。 本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据以公司定期报 告为准，敬请投资者注意投资风险。 公司 2023 年 1-8 月合并营业收入为人民币 73,441.62 万元，较去年同期的 合并营业收入减少 7.34%。与公司 2023 年 1-7 月同比减少 8.28%相比，累计营业 收入降幅收窄。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2023 年 9 月 8 日 1 证券代码：603122 证券简称：合富中国 公告编号：临 2023-027 合富（中国）医疗科技股份有限公司 2023 年 1-8 月累计营业收入简报 本公司董事会 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2023-026 合富（中国）医疗科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 重要提示： 责任。 价值在线网站 https://www.ir-online.cn 2、召开地点: 网络平台在线交流 价值在线网站 https://www.ir-online.cn 3、召开方式：网络文字互动 三、参会人员： 一、说明会类型 合富（中国）医疗科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 26 日在上海证券交易所网站（www.sse.com.cn）披露了《2023 年半年度报告全 文》及《2023 年半年度报告摘要》，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况等，公司计划于 2023 年 9 月 14 日（星期四）15:00- 会议召开时间：2023 年 9 月 14 日（星期四）15:00-16:00 会议召开地点：网络平台在线交流 会议召开方式：网络文字互动 ...

Financial Performance - Basic earnings per share decreased by 20% to CNY 0.08 compared to the same period last year[20]. - Net profit attributable to shareholders decreased by 15.30% to CNY 30,926,769.37, while net profit excluding non-recurring gains and losses decreased by 19.52% to CNY 29,505,576.13[22]. - Operating revenue declined by 9.47% to CNY 565,239,397.10 compared to the previous year[22]. - Weighted average return on equity decreased by 0.82 percentage points to 2.64%[20]. - The company reported a net cash flow from operating activities of CNY -74,738,461.70, indicating a negative cash flow situation[22]. - The company’s net assets attributable to shareholders decreased by 2.06% to CNY 1,153,448,417.77 compared to the end of the previous year[22]. - The company achieved a revenue of CNY 565.24 million in the first half of 2023, a decrease of 9.47% compared to CNY 624.35 million in the same period last year[45]. - The net profit attributable to shareholders was CNY 30.93 million, down 15.30% year-on-year[45]. - Total operating revenue for the first half of 2023 was CNY 565,239,397.10, a decrease of 9.46% compared to CNY 624,352,486.66 in the same period of 2022[135]. - Net profit for the first half of 2023 was CNY 29,612,245.54, down 23.0% from CNY 38,482,651.19 in the first half of 2022[140]. Assets and Liabilities - Total assets increased by 2.47% to CNY 1,597,604,489.20 at the end of the reporting period[22]. - The company reported a significant increase in other receivables, rising by 55.69% to 7,426,766.10 RMB, primarily due to a pending tax refund[51]. - Short-term borrowings surged by 254.53% to 181,893,903.07 RMB, mainly due to new credit and pledged loans[51]. - The company’s overseas assets totaled 192,233,574.17 RMB, representing 12.03% of total assets[52]. - Total liabilities increased to RMB 442,108,733.86 from RMB 380,491,021.65, which is an increase of approximately 16.2%[130]. - The company's equity attributable to shareholders decreased to RMB 1,153,448,417.77 from RMB 1,177,742,595.69, reflecting a decline of about 2.1%[130]. - The total current assets reached RMB 1,440,910,430.27, compared to RMB 1,411,341,524.19 at the end of 2022, indicating an increase of about 2.1%[128]. - The total non-current assets amounted to RMB 156,694,058.93, up from RMB 147,723,585.67, showing an increase of approximately 6.6%[129]. Corporate Governance and Compliance - The company did not propose a profit distribution plan or capital reserve increase plan for the reporting period[4]. - The company has not violated decision-making procedures for providing guarantees[7]. - The board of directors and management guarantee the authenticity, accuracy, and completeness of the semi-annual report[8]. - The company has committed to avoiding competition with its controlling shareholders and related parties, effective from December 15, 2020, and this commitment is ongoing[77]. - The company has established a commitment to not engage in any business that may compete with its subsidiaries, ensuring no direct or indirect involvement in competitive activities[79]. - The company has committed to transparency regarding any unfulfilled commitments, ensuring investor interests are prioritized[96]. - The company has maintained compliance with environmental regulations, with no administrative penalties reported during the reporting period[69]. - The company has not faced any penalties or corrective actions related to legal violations during the reporting period[103]. Market and Industry Insights - The in vitro diagnostic industry in China is expected to grow from CNY 170 billion in 2022 to over CNY 300 billion by 2027, driven by technological innovation and an aging population[26]. - The competition in the in vitro diagnostic reagent market is intensifying, with domestic companies holding a significant share in the immunodiagnostic field[27]. - The company faces risks from intensified market competition in the in vitro diagnostics industry, which could impact operational performance[62]. - The company has not been significantly affected by local centralized procurement policies, maintaining stable revenue and gross margins[62]. Research and Development - Research and development expenses increased by 7.87% to CNY 1.76 million, reflecting the company's commitment to innovation[47]. - The company has developed proprietary hospital department management software to enhance operational efficiency and quality of service in hospitals[33]. - The company has developed a hospital department operation management software to assist hospitals in achieving data standardization and automation[43]. Social Responsibility and Environmental Initiatives - The company actively participates in environmental protection, implementing waste classification and encouraging energy-saving practices among employees[71]. - The company donated RMB 60,000 to support educational initiatives for underprivileged youth as part of its social responsibility efforts[74]. - Medical clinical testing equipment was donated to various health institutions in Gansu Province, benefiting approximately 200-500 patients per device[74]. - The company promotes the use of biodegradable utensils in its cafeteria to reduce environmental impact[72]. - The company encourages employees to use reusable containers and has provided them with eco-friendly dining ware[72]. - The company has implemented energy-saving measures in its office, including the use of energy-efficient lighting[72]. - The company has committed to supporting rural revitalization and poverty alleviation as part of its corporate social responsibility initiatives[75]. Shareholder Information - The company’s total share capital is 398,052,633 shares, with 298,539,433 shares subject to trading restrictions[112]. - The company has released 79,601,548 restricted shares for trading, which accounts for 20.00% of the total share capital[112]. - The company’s foreign shareholding is 218,937,885 shares, representing 55.00% of the total share capital[110]. - The total number of ordinary shareholders as of the end of the reporting period is 37,144[116]. - The top ten shareholders hold a total of 218,937,885 shares, representing 55.00% of the total shares[118]. Legal and Regulatory Matters - The company reported significant legal disputes during the reporting period, with ongoing litigation involving amounts totaling approximately ¥6,235,285.19 and ¥3,117,650[100]. - The company has committed to reducing related party transactions and ensuring fair pricing to protect shareholder interests[97]. - There were no significant audit issues or non-standard audit opinions reported for the previous annual report[100]. - The company has not disclosed any major related party transactions or changes in the reporting period[104].

证券代码：603122 证券简称：合富中国 公告编号：临 2023-025 合富（中国）医疗科技股份有限公司 关于 2023 年半年度募集资金的存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准合富（中国）医疗科技股份有限公 司首次公开发行股票的批复》（证监许可〔2021〕4074号）核准，合富（中国） 医疗科技股份有限公司（以下简称"公司"）首次向社会公开发行人民币普通股 （A股）股票9,951.32万股，本次发行价格为每股人民币4.19元，募集资金总额 为人民币416,960,308.00元，扣除发行费用人民币（不含增值税）57,269,314.59 元后，实际募集资金净额为人民币359,690,993.41元。本次发行募集资金已于 2022年2月11日全部到位，并经毕马威华振会计师事务所（特殊普通合伙）审验， 于2022年2月11日出具了《验资报告》（毕马威华振验字第2200567号）。 （二）募集资 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2023-024 合富（中国）医疗科技股份有限公司 第二届监事会第六次会议决议公告 一、监事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届监事会 第六次会议于 2023 年 8 月 25 日上午在上海市虹漕路 456 号光启大楼 20 楼公司 董事会议室以现场方式召开，会议通知于 2023 年 8 月 14 日以电子邮件或书面 方式发出。会议由监事会主席陈晏女士主持，应到监事 3 人，实到监事 3 人。 会议的召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合法、 有效。 与会监事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、监事会会议审议情况 1、审议并通过了《关于公司 2023 年半年度报告及其摘要的议案》。 监事会认为：(1)公司 2023 年半年度报告及其摘要的编制和审议程序规范 合法，符合法律、法规、《公司章程》和公司内部管理制度的各项规定，内容真 实、准确、完整。 （2）公司 2023 年半年度报告及其摘要的内容和格式符合中国证监会和上 海证券交易所的各项规定，所包含的信息真实客观反映了公司 ...

合富（中国）医疗科技股份有限公司 第二届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603122 证券简称：合富中国 公告编号：临 2023-023 1 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会 第六次会议于 2023 年 8 月 25 日在上海市虹漕路 456 号光启大楼 20 楼公司董事 会议室/台北市敦化南路 2 段 76 号 23 楼以现场与视讯相结合并书面表决方式召 开，会议通知于 2023 年 8 月 14 日以电子邮件或书面方式发出。本次会议由董 事长李惇先生主持，应到董事 7 人，实到董事 7 人，部分监事和高级管理人员 列席了会议。会议的召开符合法律法规、《公司法》及《公司章程》的规定，会 议决议合法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 1、审议并通过了《关于公司 2023 年半年度报告及其摘要的议案》。 具体内容详见公司同日在上海证券交易所网站（www.sse.c ...

1、关于 2023 年半年度募集资金的存放与实际使用情况专项报告的议案 合富（中国）医疗科技股份有限公司独立董事 关于公司第二届董事会第六次会议审议的相关事项 的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事规则》、《上市公司治理准则》、《合富（中国）医疗科技股份有限公司章程》 等有关规定，作为合富（中国）医疗科技股份有限公司（以下简称"公司"）的 独立董事，基于独立、客观判断的原则，我们对公司第二届董事会第六次会议审 议的相关事项发表独立意见如下： 经审慎查验，我们认为：公司 2023 年半年度募集资金存放与实际使用情况 符合法律法规和公司《募集资金管理制度》的规定，公司对募集资金进行了专户 存储和专项使用，不存在违规存放与使用募集资金的情形。同时，公司《2023 年 半年度募集资金的存放与实际使用情况专项报告》内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏，真实、客观地反映了公司 2023 年 半年度募集资金存放与使用情况。 合富（中国）医疗科技股份有限公司 独立董事：Stanley Yi Chang、雷永耀、周露露 2023 年 8 月 25 ...

特此公告。 合富（中国）医疗科技股份有限公司董事会 2023 年 1-7 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"） 之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买卖 中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收入数 据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海证券交 易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、《证券日 报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司营业收入。 本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据以公司定期报 告为准，敬请投资者注意投资风险。 公司 2023 年 1-7 月累计合并营业收入为人民币 64,462.77 万元，较去年同 期的合并营业收入减少 8.28%。 证券代码：603122 证券简称：合富中国 公告编号：临 2023-022 合富（中国）医疗科技 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥267,190,714.93, representing a decrease of 13.25% compared to the same period last year[5] - Net profit attributable to shareholders was ¥9,222,339.66, down 39.09% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥9,797,345.31, a decrease of 37.00% compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.02, reflecting a decline of 60.00% year-on-year[5] - Total operating revenue for Q1 2023 was ¥267,190,714.93, a decrease of 13.3% compared to ¥307,984,973.42 in Q1 2022[18] - Net profit for Q1 2023 was ¥9,111,154.02, a decline of 40.0% from ¥15,156,422.19 in Q1 2022[19] - Earnings per share for Q1 2023 were ¥0.02, compared to ¥0.05 in Q1 2022[20] Cash Flow and Liquidity - The net cash flow from operating activities was -¥113,986,510.74, indicating a significant cash outflow[5] - In Q1 2023, the company's cash inflow from operating activities was CNY 254,639,895.29, a decrease of 3.8% compared to CNY 264,643,033.90 in Q1 2022[22] - The net cash outflow from operating activities was CNY -113,986,510.74, worsening from CNY -67,054,010.90 in the same period last year[22] - The company's cash and cash equivalents decreased significantly, impacting liquidity ratios[19] - Cash inflow from financing activities totaled CNY 112,061,541.77, a decrease of 75% from CNY 448,199,884.89 in Q1 2022[23] - The net cash flow from financing activities was CNY 30,656,394.52, down from CNY 326,273,822.10 in the same quarter last year[23] - The company's cash and cash equivalents at the end of Q1 2023 were CNY 228,813,378.42, down from CNY 392,401,162.51 at the end of Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,507,131,250.60, down 3.33% from the end of the previous year[5] - Total assets as of Q1 2023 amounted to ¥1,507,131,250.60, a decrease from ¥1,559,065,109.86 in the previous year[16] - Total liabilities for Q1 2023 were ¥321,349,173.08, down from ¥380,491,021.65 in Q1 2022[16] - Cash and cash equivalents as of March 31, 2023, amounted to RMB 241,769,403.33, down from RMB 326,855,769.22 as of December 31, 2022[14] - Accounts receivable increased to RMB 794,485,889.13 from RMB 746,897,311.83 year-over-year[14] - Total current assets decreased to RMB 1,354,330,563.06 from RMB 1,411,341,524.19[14] - Inventory as of March 31, 2023, was RMB 201,481,116.36, slightly down from RMB 204,822,603.19[14] Shareholder Information - Total number of common shareholders at the end of the reporting period was 40,762[11] - The largest shareholder, 合富（香港）控股有限公司, holds 218,937,885 shares, representing 55.00% of total shares[11] - The report indicates that there are no known relationships or concerted actions among the top shareholders[12] Operational Insights - The decline in net profit was primarily due to reduced service volume from end hospitals and decreased reagent procurement by customers[8] - The company's COVID-19 testing business had a minimal impact on the overall net profit, with only ¥760,000 in gross profit from related operations in the previous year[8] - The company expanded its sales, marketing, and R&D teams, leading to increased employee compensation and marketing expenses[8] - The company has not disclosed any new product or technology developments in the current report[13] - There are no significant mergers or acquisitions reported during the period[13] - The company has not provided specific future guidance or market expansion strategies in the current report[13] - Research and development expenses increased to ¥616,123.18 in Q1 2023 from ¥459,910.51 in Q1 2022, reflecting a focus on innovation[19] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,903,164.70 in Q1 2023 compared to -¥729,314.51 in Q1 2022[20] - The company is exploring market expansion strategies to recover from the decline in revenue and profit margins[19]

重要提示： 责任。 价值在线网站 https://www.ir-online.cn/ 会议召开方式：网络文字互动 投资者可于 2023 年 4 月 14 日（星期五）15:00 前将需要了解的情况和 有 关 问 题 预 先 通 过 电 子 邮 件 的 形 式 发 送 至 公 司 投 资 者 关 系 邮 箱 ： ir_cowealth@cowealth.com，也可通过访问网址 https://eseb.cn/13BAUw4QtsA 或使用微信扫描下方小程序码进行会前提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 证券代码：603122 证券简称：合富中国 公告编号：临 2023-015 合富（中国）医疗科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 一、说明会类型 合富（中国）医疗科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 22 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年经营成果、财务状况，公司计 ...